| 000 | 01615cam a2200349 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030752.0 | ||
| 008 | 130218s2012 ua dh f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.08.10.M.Sc.2012.Mo.P | ||
| 100 | 0 | _aMohammed Yousef Salem Abary | |
| 245 | 1 | 0 |
_aPharmaceutical study on paroxetine / _cMohammed Yousef Salem Abary ; Supervised Mohamed Ahmed Elnabarawi , Ehab Rasmy Bendas , Randa Tag Abdelrehem |
| 246 | 1 | 5 | _aدراسة صيدلية على عقار الباروكستين |
| 260 |
_aCairo : _bMohammed Yousef Salem Abary , _c2012 |
||
| 300 |
_a239P. : _bcharts , facsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Pharmacy - Department of Industrial Pharmacy | ||
| 520 | _aParoxetine liposomes vesicles (PLVs) were prepared using reverse-phase evaporation technique . The lipid components were (lecithin soybean phosphatidylcholine (LSPC) either alone or mixed with other lipids such as cholesterol (CHOL) . The in-vitro permeation studies revealed that paroxetine was permeated in a higher rate and extent from liposomal formula F5 (7:7) molar ratio | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aGel | |
| 653 | 4 | _aLiposomes | |
| 653 | 4 | _aParoxetine | |
| 700 | 0 |
_aEhab Rasmy Bendas , _eSupervisor |
|
| 700 | 0 |
_aMohamed Ahmed Elnabarawi , _eSupervisor |
|
| 700 | 0 |
_aRanda Tag Abdelrehem , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aFatma _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c41553 _d41553 |
||